Sarepta Therapeutics Announces First Quarter 2022 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Sarepta Therapeutics (SRPT) Posts Smaller Q1 Loss
May 4, 2022 5:22 PM EDTSarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($0.56), $0.71 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $188.8 million versus the consensus estimate of $206.44 million.
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
... More